Keely May McNamara1, Saki Oguro2, Fumiya Omata2, Kyoko Kikuchi2, Fouzia Guestini2, Koyu Suzuki3, Yang Yang3, Eriko Abe3, Hisashi Hirakawa4, Kristy A Brown5, Ishida Takanori2, Noriaki Ohuchi2, Hironobu Sasano2. 1. Department of Anatomical Pathology and Surgery, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. kmcnamara@patholo2.med.tohoku.ac.jp. 2. Department of Anatomical Pathology and Surgery, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. 3. Departments of Pathology and Surgery, St Lukes Hospital, Tokyo, Japan. 4. Department of Pathology, Tohoku Kosai Hospital, Sendai, Japan. 5. Hudson Institute of Medical Research, Department of Molecular and Translational Science, Monash University, Clayton, VIC, Australia.
Abstract
PURPOSE: While triple-negative breast cancer (TNBC) is negative for estrogen receptor alpha, a substantial proportion of carcinomas express estrogen receptor beta (ERβ); consequently, estrogen actions and metabolism may be relevant in this cancer subtype. METHODS: A cohort of 81 TNBC patients from Tohoku University Hospital, Japan were characterised with regard to the expression of estrogen receptor beta and enzymes known to modulate levels of estrogens in breast and other tissues (Aromatase, 17-beta- Hydroxysteroid dehydrogenases 1, 2 and 6). This was done at the protein level by means of immunohistochemistry. As this cohort has been previously characterised for androgens, this also allows for comparison between the expressions of estrogen-related proteins and of androgen-related proteins. Preliminary mechanistic studies in cell culture were also undertaken. RESULTS: 17βHSD2 was detected in the highest number of cases followed by 17βHSD1, 17βHSD6 and aromatase. When comparing the expression of ERβ with that of the enzymes, it was positively correlated with the expression of 17βHSD6 (p < 0.05) and trended towards correlation with dual expression of 17βHSD1 and 2 (p < 0.07). 17βHSD1 was associated with significantly reduced tumour volume (p = 0.0025), while ERβ was associated with a trend towards reduced lymphovascular invasion, (p < 0.061). Interestingly, in survival analysis, 17βHSD6 expression was the only one of these five factors that influenced survival, with positive samples being associated with longer disease-free survival compared to those that were negative for 17βHSD6 (p < 0.05). In assessing associations with expression of proteins in the androgenic pathway, expression of aromatase appeared to be associated with androgenic pathways in TNBC patients (p < 0.05). Due to this association and the potential relevance to androgen-directed therapies in TNBC, we evaluated this interaction in vitro. We observed androgen-dependent upregulation of aromatase and ERβ in a subset of AR expressing TNBC cell lines (MDA-MB-453, SUM-185-PE and MFM-223). CONCLUSION: Overall this study suggests the presence of, and a potential protective effect of estrogens in TNBC.
PURPOSE: While triple-negative breast cancer (TNBC) is negative for estrogen receptor alpha, a substantial proportion of carcinomas express estrogen receptor beta (ERβ); consequently, estrogen actions and metabolism may be relevant in this cancer subtype. METHODS: A cohort of 81 TNBC patients from Tohoku University Hospital, Japan were characterised with regard to the expression of estrogen receptor beta and enzymes known to modulate levels of estrogens in breast and other tissues (Aromatase, 17-beta- Hydroxysteroid dehydrogenases 1, 2 and 6). This was done at the protein level by means of immunohistochemistry. As this cohort has been previously characterised for androgens, this also allows for comparison between the expressions of estrogen-related proteins and of androgen-related proteins. Preliminary mechanistic studies in cell culture were also undertaken. RESULTS: 17βHSD2 was detected in the highest number of cases followed by 17βHSD1, 17βHSD6 and aromatase. When comparing the expression of ERβ with that of the enzymes, it was positively correlated with the expression of 17βHSD6 (p < 0.05) and trended towards correlation with dual expression of 17βHSD1 and 2 (p < 0.07). 17βHSD1 was associated with significantly reduced tumour volume (p = 0.0025), while ERβ was associated with a trend towards reduced lymphovascular invasion, (p < 0.061). Interestingly, in survival analysis, 17βHSD6 expression was the only one of these five factors that influenced survival, with positive samples being associated with longer disease-free survival compared to those that were negative for 17βHSD6 (p < 0.05). In assessing associations with expression of proteins in the androgenic pathway, expression of aromatase appeared to be associated with androgenic pathways in TNBC patients (p < 0.05). Due to this association and the potential relevance to androgen-directed therapies in TNBC, we evaluated this interaction in vitro. We observed androgen-dependent upregulation of aromatase and ERβ in a subset of AR expressing TNBC cell lines (MDA-MB-453, SUM-185-PE and MFM-223). CONCLUSION: Overall this study suggests the presence of, and a potential protective effect of estrogens in TNBC.
Authors: I Armasu; C Preda; V Ianole; V Mocanu; I Hristov; E C Andriescu; I Cretu-Silivestru; I Vasiliu; C G Dascalu; C D Lupascu; I Crumpei; D N Serban; I L Serban; D G Ciobanu Apostol Journal: Acta Endocrinol (Buchar) Date: 2020 Jan-Mar Impact factor: 0.877
Authors: Wanfu Wu; Margaret Warner; Li Wang; Wei-Wei He; Ruipeng Zhao; Xiaoxiang Guan; Cindy Botero; Bo Huang; Charlotte Ion; Charles Coombes; Jan-Ake Gustafsson Journal: Proc Natl Acad Sci U S A Date: 2021-08-17 Impact factor: 11.205
Authors: Keely M McNamara; Fouzia Guestini; Torill Sauer; Joel Touma; Ida Rashida Bukholm; Jonas C Lindstrøm; Hironobu Sasano; Jürgen Geisler Journal: Br J Cancer Date: 2018-03-22 Impact factor: 7.640